Literature DB >> 8707764

Coagulation disorders in cancer.

K E Goad1, H R Gralnick.   

Abstract

Coagulation disorders are common in cancer patients. This article reviews the coagulation laboratory findings in these patients and the thromboembolic and hemorrhagic manifestations of malignancy. Among the many topics addressed are Trousseau's syndrome, disseminated intravascular coagulation, and acquired von Willebrand disease. Pathogenesis of the coagulation disorders and recommendations for treatment of various syndromes are discussed.

Entities:  

Mesh：

Year:  1996        PMID： 8707764     DOI： 10.1016/s0889-8588(05)70347-6

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  11 in total

1.  Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer.

Authors:  Evren Fidan; Halil Kavgaci; Asim Orem; Mustafa Yilmaz; Bulent Yildiz; Sami Fidan; Buket Akcan; Feyyaz Ozdemir; Fazil Aydin
Journal:  Tumour Biol       Date:  2012-04-27

Review 2.  Trousseau's syndrome: multiple definitions and multiple mechanisms.

Authors:  Ajit Varki
Journal:  Blood       Date:  2007-05-11       Impact factor: 22.113

3.  Associations of factor VIIIc, D-dimer, and plasmin-antiplasmin with incident cardiovascular disease and all-cause mortality.

Authors:  Aaron R Folsom; Joseph A C Delaney; Pamela L Lutsey; Neil A Zakai; Nancy S Jenny; Joseph F Polak; Mary Cushman
Journal:  Am J Hematol       Date:  2009-06       Impact factor: 10.047

4.  Prognostic role of D-dimer in patients with lung cancer: a meta-analysis.

Authors:  Xuelei Ma; Yanyan Li; Jing Zhang; Jingwen Huang; Lei Liu
Journal:  Tumour Biol       Date:  2013-10-10

5.  Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS-13 in patients with lung cancer.

Authors:  Xia Liu; Xiaogang Chen; Jiezuan Yang; Renyong Guo
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

6.  Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small-cell lung cancer.

Authors:  Renyong Guo; Jiezuan Yang; Xia Liu; Jianping Wu; Yu Chen
Journal:  J Clin Lab Anal       Date:  2017-04-04       Impact factor: 2.352

7.  Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer.

Authors:  Katsuhiro Masago; Shiro Fujita; Tadashi Mio; Yosuke Togashi; Young Hak Kim; Yukimasa Hatachi; Akiko Fukuhara; Kaoru Irisa; Yuichi Sakamori; Michiaki Mishima
Journal:  Med Oncol       Date:  2010-03-19       Impact factor: 3.064

Review 8.  Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

9.  [Pre-operative plasma D-dimer level may predict the poor prognosis within one year after the surgery for non-small cell lung cancer].

Authors:  Zhe Wang; Junke Fu; Dongmei Diao; Chengxue Dang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-06

10.  Distal Medullary Canal Decompression in Long Stem Hip Replacement in Long Bone Metastasis: Does it Reduce Cardiopulmonary Complications?

Authors:  Vivek Ajit Singh; Siamak Sarrafan; Ramesh Singh Veriah
Journal:  Indian J Orthop       Date:  2018 Jan-Feb       Impact factor: 1.251
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.